Clinical Trials
-
Principal Investigator:
Sharon L Wardlaw, MDThe goal of this project is to understand why bariatric surgery is such an effective treatment for obesity with a focus on brain mechanisms. Cerebrospinal fluid neuropeptides, hormones, and protein levels will be measured in subjects before and after bariatric surgery as compared with subjects before and after diet-induced weight loss. Participants in the diet arm will follow a low-calorie liquid diet (Optifast) for approximately 12 weeks. They will have two lumbar punctures (spinal taps) and liquid test meal challenges, as well as weekly nutritionist counseling. These participants will... -
Principal Investigator:
Ilene Fennoy, MDWe know that puberty is a major time of change! Adolescents develop new decision-making skills and independence. It is possible that some of these changes are due to the hormonal changes during puberty. One of the ways we treat transgender and gender non-conforming teens is to suppress or "block" puberty. We know that this is a safe thing to do for teens because we use it in people who start puberty too early (precocious puberty) and in people who are born very small in order to prolong their growth potential. We are doing this study to continue to understand the impact of this therapy on... -
Principal Investigator:
Pamela U Freda, MDGrowth hormone and insulin-like growth-factor 1 (IGF-1) are two hormones that are very important to human growth and metabolism. In disorders of GH and IGF-1 excess and deficiency, significant growth and metabolic abnormalities can develop. This study investigates the effects of GH on the appetite-stimulating hormone AgRP (agouti-related peptide) and the effect of the weight loss medication "Liraglutide" on AgRP. This study is open to healthy subjects and patients with known GH deficiency who are between the ages of 18 and 45. Study participants will be asked to come for a screening visit and... -
Principal Investigator:
Robin S. Goland, MDA future without Type 1 Diabetes (T1D) starts with you. Get screened! Thanks in large part to T1D family members, we understand T1D as a disease that progresses in three distinct stages. This new definition in conjunction with TrialNet's Pathway to Prevention screening, allows for earlier detection and intervention. -
Principal Investigator:
Robin S. Goland, MDA future without Type 1 Diabetes (T1D) starts with you. Get screened! Thanks in large part to T1D family members, we understand T1D as a disease that progresses in three distinct stages. This new definition in conjunction with TrialNet's Pathway to Prevention screening, allows for earlier detection and intervention. -
Principal Investigator:
Rudolph L. Leibel, MDThe Physiology of the Weight Reduced State (POWERS) is a national research study designed to discover and learn what happens to the human body after weight loss and to learn why some people regain their lost weight. Understanding why this happens could help health professionals improve strategies for successful weight loss maintenance after weight loss. POWERS is a research study with a goal to understand the changes in the body that occur after weight loss and learn how these changes affect the ability to keep the weight off. It involves universities, medical centers, researchers, and most... -
Principal Investigator:
Ilene Fennoy, MDWe are doing this research study to find out what happens to children who are overweight and how the things we recommend as a part of routine clinical care affect your child. The purpose of this study is to understand what happens to children as a result of being overweight, to link these outcomes to specific clinical measures, and to determine how treatment affects the physical and clinical features of overweight or obesity. To achieve this aim we want to formalize our ongoing clinical chart review into a database for our patients. -
Principal Investigator:
Blandine Laferrère, MD, PhDThis is a randomized trial that will examine the effect of self-monitoring food intake via a smartphone application, and of a novel lifestyle intervention called time-restricted eating, on improvement of metabolic health in persons with overweight or obesity. The intervention lasts 12 months and will be administered via a smartphone app. Participants will use the app to take pictures of all food and drinks, every day for 3 months, then 10 days a month for the following 9 months. Participation requires one screening visit (~1hr), and eight outpatient visits (~1-5hr) including an IV catheter in... -
Principal Investigator:
Robin S. Goland, MDThe purpose of this study is to learn if the use of two drugs, Rituximab and Abatacept, one after the other, will help to extend insulin production in people newly diagnosed with type 1 diabetes (T1D). These two medications may potentially help each other with altering the immune response that causes the attack on insulin-secreting cells in the pancreas. T1D RELAY will study if two treatments consecutively performs better than Rituximab alone. Researchers will test if those who are also treated with Abatacepthave better C-peptide levels over time. -
Principal Investigator:
Judy Korner, MDThe purpose of this study is to evaluate if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The participation lasts ten months and includes six in-person visits at CUIMC with blood sampling and questionnaires, virtual nutritional counseling, and taking an oral weight loss medication for 28 weeks.